In vitro fertilization (IVF) has revolutionized the treatment of infertility, offering hope to millions of couples globally. This review synthesizes contemporary strategies in IVF, emphasizing evidence-based clinical decision-making. We discuss epidemiology, pathophysiology, risk factors, clinical features, diagnostic approaches, and treatment modalities, with a focus on recent advances, emerging therapies, and guideline-based management. By integrating current research and expert consensus, this article aims to provide clinicians with an in-depth, pragmatic resource to optimize IVF outcomes and patient care.
Infertility affects a substantial proportion of reproductive-age couples worldwide, with IVF serving as a cornerstone of assisted reproductive technology (ART). The landscape of IVF is rapidly evolving, driven by advances in embryology, genomics, and reproductive endocrinology. For healthcare professionals, staying abreast of these developments is essential for individualized patient care. This review examines the latest strategies in IVF, guiding clinical decision-making through the lens of recent scientific evidence and established guidelines.
Infertility affects 8-12% of couples globally, with a rising trend attributed to delayed childbearing, lifestyle factors, and environmental exposures. IVF accounts for over 2 million cycles annually worldwide. The disease burden is not only medical but also psychological and socioeconomic, impacting quality of life, marital relationships, and healthcare systems. Regional disparities in access, success rates, and regulatory frameworks further complicate the epidemiological landscape, underscoring the need for uniform, evidence-based approaches to patient selection and management.
IVF addresses multifactorial etiologies of infertility, including anovulation, tubal pathology, male factor infertility, and unexplained cases. The underlying pathophysiology often involves hormonal imbalances, impaired gametogenesis, tubal occlusion, or immunological mechanisms. Advances in molecular biology have elucidated genetic and epigenetic contributors to infertility, informing targeted interventions and prognostic stratification. Understanding these mechanisms is critical for tailoring IVF protocols and optimizing fertilization and implantation outcomes.
Key risk factors influencing IVF candidacy and outcomes include advanced maternal age, diminished ovarian reserve, poor semen parameters, endometriosis, polycystic ovary syndrome (PCOS), obesity, and lifestyle factors such as smoking and alcohol use. Iatrogenic risks, including previous ovarian surgery or chemotherapy, must also be considered. Comprehensive risk assessment enables clinicians to counsel patients regarding prognosis, adjust protocols, and implement adjunctive therapies where appropriate.
Patients presenting for IVF typically report prolonged infertility, failed prior fertility treatments, or known reproductive pathologies. Clinical features vary depending on the underlying cause: anovulation may manifest as irregular cycles; tubal factors as a history of pelvic inflammatory disease or ectopic pregnancy; male factor as abnormal semen analysis. A thorough clinical evaluation, including reproductive history and physical examination, is essential for individualized treatment planning.
Diagnosis in IVF involves a comprehensive workup for both partners. Female assessment includes ovarian reserve testing (AMH, FSH, AFC), tubal patency evaluation (HSG, laparoscopy), and uterine cavity assessment (ultrasound, hysteroscopy). Male evaluation requires semen analysis and, if indicated, genetic testing or testicular biopsy. Pre-implantation genetic testing (PGT) is increasingly utilized to screen embryos for aneuploidy or monogenic disorders, enhancing embryo selection and improving success rates.
IVF treatment comprises controlled ovarian stimulation (COS), oocyte retrieval, fertilization, embryo culture, and embryo transfer. COS protocols are individualized based on age, ovarian reserve, and previous response, aiming to maximize yield while minimizing ovarian hyperstimulation syndrome (OHSS). Fertilization techniques include conventional IVF and intracytoplasmic sperm injection (ICSI), with the latter indicated for severe male factor infertility. Embryo transfer decisions—timing, number, and stage (cleavage vs. blastocyst)—are guided by embryo quality and patient characteristics. Luteal phase support and adjunctive interventions, such as endometrial receptivity testing or immunomodulation, may be considered.
Recent innovations in IVF include time-lapse embryo imaging, artificial intelligence (AI)-assisted embryo selection, vitrification for oocyte/embryo cryopreservation, and non-invasive pre-implantation genetic testing (niPGT). The implementation of freeze-all strategies, elective single embryo transfer (eSET), and personalized COS protocols has reduced complications while improving cumulative live birth rates. Research into mitochondrial replacement, stem cell-derived gametes, and endometrial microbiome modulation holds promise for future clinical application. Integration of omics data and AI-driven analytics is poised to refine prognostication and personalize care further.
International and national guidelines, such as those from ESHRE and ASRM, emphasize individualized care, safety, and efficacy in IVF. Key recommendations include comprehensive pre-treatment evaluation, judicious use of COS protocols, preference for eSET to reduce multiple pregnancies, and consideration of PGT in selected cases. Guidelines advocate for patient-centered decision-making, informed consent, and psychosocial support. Adherence to quality assurance frameworks and registry reporting ensures ongoing improvement and accountability in IVF practice.
Modern strategies in IVF have substantially advanced the field of reproductive medicine, offering effective, safe, and patient-tailored interventions for infertility. Clinicians must assimilate evolving evidence, guideline recommendations, and technological innovations to inform clinical decision-making. Ongoing research and multidisciplinary collaboration are essential to further optimize IVF outcomes, minimize risks, and enhance patient experience in this complex and rapidly changing domain.
1.
Reduced Suicide Rates in Cancer Patients; Enhanced Circadian Rhythm; HIV Vaccine for Cancer Patients?
2.
DNA's hidden shape reveals target to reverse ovarian cancer chemoresistance
3.
For patients with prostate cancer, long-term follow-up helps identify treatment side effects.
4.
Can patients receiving immunotherapy for cancer benefit from taking vitamin D supplements?
5.
Chemotherapy can be a challenging treatment?here's how to deal with some of the side-effects
1.
Blastic Plasmacytoid Dendritic Cell Neoplasm and the Dawn of AI-powered Diagnostics
2.
Unlocking the Secrets of Squamous Cell Carcinoma: New Hope for Patients
3.
Precision Cancer Risk Mitigation Strategies
4.
Unlocking the Mysteries of Lymphoblastic Lymphoma: A Journey Into the Unknown
5.
Exploring the Use of Bevacizumab in Treating Different Types of Cancers
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
2.
Efficient Management of First line ALK-rearranged NSCLC - Part II
3.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
4.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
5.
Innovations in Hematology
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation